Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

pirtobrutinib 3Cyclophosphamide 3Azacitidine 3ibrutinib 2fludarabine 2Mycophenolic Acid 2Lenalidomide 2zanubrutinib 1venetoclax 1ruxolitinib 1ponatinib 1nilotinib 1idelalisib 1idecabtagene vicleucel 1fludarabine phosphate 1cedazuridine 1cc-486 1asciminib 1acalabrutinib 1Whole-Body Irradiation 1Vancomycin 1Tretinoin 1Tacrolimus 1Sirolimus 1Semen Analysis 1Rituximab 1Quality of Life 1Physical Examination 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × idelalisib × 90 days × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡